XML 64 R52.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Reporting (Selected Financial Information by Reporting Segment) (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
segment
Sep. 30, 2023
USD ($)
Segment Reporting Information [Line Items]        
Number of Reportable Segments     2  
Net revenues:        
Revenues $ 191,214,000 $ 180,556,000 $ 545,444,000 $ 466,290,000
Gross profit (loss):        
Gross Profit 101,941,000 108,403,000 287,207,000 254,981,000
Operating Expenses 44,893,000 35,725,000 126,932,000 111,974,000
Income from operations 57,048,000 72,678,000 160,275,000 143,007,000
Non-operating income (expenses) (9,365,000) (9,041,000) (14,473,000) (12,993,000)
Income (loss) before income taxes 47,683,000 63,637,000 145,802,000 130,014,000
Finished Pharmaceutical Products Segment        
Net revenues:        
Revenues 189,752,000 176,366,000 538,755,000 455,242,000
Gross profit (loss):        
Gross Profit 105,544,000 109,499,000 302,322,000 262,742,000
Active Pharmaceutical Ingredient Segment        
Net revenues:        
Revenues 1,462,000 4,190,000 6,689,000 11,048,000
Gross profit (loss):        
Gross Profit $ (3,603,000) $ (1,096,000) $ (15,115,000) $ (7,761,000)